Biocon Share Price
- All
- News
-
Biocon Declines Over 3% After Net Profit Increased 105% In March Quarter
Biocon Share Price Today: On Friday, Biocon opened on the BSE at Rs 392, touching an intra day high of Rs 392 and an intra day low of Rs 380.55, in the trading session so far.
-
Biocon Net Profit Jumps 105% To Rs 254 Crore In March Quarter
Biocon Q4 Results: Biocon's consolidated revenue increased 26 per cent in the fourth quarter of the fiscal 2020-21 to Rs 2,044 crore, compared to Rs 1,621 crore in the corresponding quarter last year.
-
Biocon Shares Fall After Profit Declines In December Quarter
On a standalone basis, Biocon's profit plunged 72 per cent annually to Rs 33 crore from Rs 121 crore during the same period last year.
-
Biocon To Buy 26% Stake In Hinduja Renewables Two
"The cost of the acquisition is Rs 5,91,61,730 for the acquisition of 26 per cent stake on a fully diluted basis in one or more tranches," the Bangalore-based Biocon said in a BSE filing.
-
Biocon Soars Nearly 10% On Receiving Nod For Covid-19 Drug
Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.
-
Syngene Makes Stellar Debut, Surges 27% on Listing
Syngene International's IPO was subscribed over 32 times last month, helping it raise an estimated Rs 550 crore. The company had also raised Rs 150 crore from anchor investors. The IPO had opened on July 27 and closed on July 29.
-
Syngene International IPO Subscribed 32% on Day 1: Read This Before Investing
Syngene International is offering 2.2 crore shares in the price band of Rs 240-Rs 250. The issue is essentially an offer for sale wherein proceeds from the IPO will not be ploughed back in the company. Its parent Biocon is selling 11 per cent stake in the company which will bring down its stake to 74.5 per cent from 85.5 per cent now.
-
Biocon Declines Over 3% After Net Profit Increased 105% In March Quarter
Biocon Share Price Today: On Friday, Biocon opened on the BSE at Rs 392, touching an intra day high of Rs 392 and an intra day low of Rs 380.55, in the trading session so far.
-
Biocon Net Profit Jumps 105% To Rs 254 Crore In March Quarter
Biocon Q4 Results: Biocon's consolidated revenue increased 26 per cent in the fourth quarter of the fiscal 2020-21 to Rs 2,044 crore, compared to Rs 1,621 crore in the corresponding quarter last year.
-
Biocon Shares Fall After Profit Declines In December Quarter
On a standalone basis, Biocon's profit plunged 72 per cent annually to Rs 33 crore from Rs 121 crore during the same period last year.
-
Biocon To Buy 26% Stake In Hinduja Renewables Two
"The cost of the acquisition is Rs 5,91,61,730 for the acquisition of 26 per cent stake on a fully diluted basis in one or more tranches," the Bangalore-based Biocon said in a BSE filing.
-
Biocon Soars Nearly 10% On Receiving Nod For Covid-19 Drug
Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.
-
Syngene Makes Stellar Debut, Surges 27% on Listing
Syngene International's IPO was subscribed over 32 times last month, helping it raise an estimated Rs 550 crore. The company had also raised Rs 150 crore from anchor investors. The IPO had opened on July 27 and closed on July 29.
-
Syngene International IPO Subscribed 32% on Day 1: Read This Before Investing
Syngene International is offering 2.2 crore shares in the price band of Rs 240-Rs 250. The issue is essentially an offer for sale wherein proceeds from the IPO will not be ploughed back in the company. Its parent Biocon is selling 11 per cent stake in the company which will bring down its stake to 74.5 per cent from 85.5 per cent now.
